Centene to Present at UBS 2025 Healthcare Conference

Centene ( (CNC) ) has issued an update.

Centene Corporation announced its participation in the UBS 2025 Global Healthcare Conference on November 11, 2025, where it will discuss its financial outlook. The company maintains its forecast of a diluted loss per share not exceeding $(12.85) and an adjusted diluted EPS of at least $2.00 for the full year 2025. Centene emphasizes the use of non-GAAP financial measures to provide a clearer understanding of its core performance, excluding certain expenses and amortizations, to better assess its ongoing operations and performance consistency.

The most recent analyst rating on (CNC) stock is a Hold with a $44.00 price target. To see the full list of analyst forecasts on Centene stock, see the CNC Stock Forecast page.

Spark’s Take on CNC Stock

According to Spark, TipRanks’ AI Analyst, CNC is a Neutral.

Centene’s overall stock score reflects a combination of mixed financial performance and positive technical and valuation indicators. The most significant factor is the financial performance, which shows challenges in profitability despite positive revenue growth and cash flow improvements. Technical analysis indicates short-term momentum, while valuation suggests the stock may be undervalued. The earnings call provided a positive outlook, but highlighted ongoing challenges that could impact future performance.

To see Spark’s full report on CNC stock, click here.

More about Centene

Centene Corporation operates in the healthcare industry, providing services primarily focused on government-sponsored healthcare programs. The company is known for its managed care offerings, which include Medicaid, Medicare, and Health Insurance Marketplace services, positioning it as a significant player in the healthcare sector.

Average Trading Volume: 12,417,291

Technical Sentiment Signal: Sell

Current Market Cap: $18.46B

For a thorough assessment of CNC stock, go to TipRanks’ Stock Analysis page.